HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News May 31, 2022 0 Karyopharm Therapeutics: CHMP Recommended Approval of the Firm’s Product NEXPOVIO® for Multiple Melanoma in Europe. May 20, 2022 0 Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold May 2, 2022 0 Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings April 27, 2022 0